Teachers Retirement System of The State of Kentucky Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Teachers Retirement System of The State of Kentucky bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 20,200 shares of the company's stock, valued at approximately $909,000.

Several other institutional investors and hedge funds have also bought and sold shares of PTGX. GAMMA Investing LLC lifted its stake in Protagonist Therapeutics by 749.2% in the third quarter. GAMMA Investing LLC now owns 552 shares of the company's stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Protagonist Therapeutics in the 3rd quarter valued at about $43,000. CWM LLC lifted its stake in Protagonist Therapeutics by 910.3% in the 3rd quarter. CWM LLC now owns 1,273 shares of the company's stock valued at $57,000 after purchasing an additional 1,147 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new position in Protagonist Therapeutics during the third quarter worth about $69,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Protagonist Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock worth $95,000 after purchasing an additional 379 shares during the period. Institutional investors own 98.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PTGX shares. Wedbush reaffirmed an "outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group began coverage on Protagonist Therapeutics in a report on Friday, December 6th. They set a "neutral" rating and a $47.00 price target for the company. BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $62.00 price objective on the stock. StockNews.com cut shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Finally, TD Cowen raised shares of Protagonist Therapeutics to a "strong-buy" rating in a report on Wednesday, September 25th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.78.

Protagonist Therapeutics Stock Up 1.3 %

Shares of Protagonist Therapeutics stock traded up $0.52 during trading on Thursday, reaching $39.54. The company's stock had a trading volume of 747,094 shares, compared to its average volume of 741,659. The business's 50-day moving average price is $44.17 and its 200-day moving average price is $40.81. Protagonist Therapeutics, Inc. has a 52 week low of $20.71 and a 52 week high of $48.89. The firm has a market cap of $2.36 billion, a PE ratio of 14.86 and a beta of 2.18.

Insiders Place Their Bets

In related news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the firm's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.96, for a total value of $3,687,299.20. Following the transaction, the chief executive officer now owns 435,208 shares in the company, valued at approximately $20,437,367.68. This trade represents a 15.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Arturo Md Molina sold 1,906 shares of the company's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the sale, the insider now directly owns 46,444 shares of the company's stock, valued at $1,903,275.12. This represents a 3.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 209,863 shares of company stock worth $9,689,847 in the last quarter. 5.40% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.